SPECIAL REPORT
MOST SHARED
- Europe May Be Unprepared for Greece Exit: Official
- How Boaz Weinstein and Hedge Funds Outsmarted JPMorgan
- Marc Faber: 100% Chance of Global Recession
- Buying the Right Sell-Off Stocks
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- What Would Greek Exit Mean for the US Economy?
- Steve Jobs and Mickey Drexler: A Tale of Two Retailers
- Are Investors Running Out of Safe Havens to Put Money?
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Weinstein, Hedge Funds Outsmarted JPMorgan
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
Battlin' Over Amylin
 |
CNBC.com |
Yesterday I wrote about the timing of the back-to-back press releases out of Amylin Pharmaceuticals. The first one announced a significant sales force cut and the second one heralded the earlier-than-expected filing for FDA approval of the once-a-week diabetes drug Byetta. Eli Lilly and Alkermes are partners with AMLN on the long-acting tummy injection. Tuesday afternoon on CNBC's "Street Signs," LLY's Chairman and CEO John Lechleiter told David Faber he expects the FDA to take about a year to review the application.
Icahn and another big investor, Eastbourne Capital Management, which owns 12.5 percent of AMLN, are campaigning to get their people on the company's Board of Directors. The annual shareholder meeting is at the end of this month. Icahn filed a proxy statement with the SEC today. But Eastbourne almost simultaneously posted an even juicier addition to its proxy materials. The group cites the 75 percent drop in AMLN shares over the past couple of years and claims that's the third-worst performance among the 20 companies in the AMEX Biotech Index since August 2007.
In the document Eastbourne's Founder and Portfolio Manager, Rick Barry, labels the current board "incapable" and he also questions the confluence of this week's Amylin announcements. "It is not surprising to us that Amylin has been able to advance its timetable and submit a New Drug Application for (Byetta) Once-Weekly as we approach this year's annual meeting....We are also struck by the timing of the apparent realization by Amylin's management, reflected in the company's just announced 'New Sales Approach,' that the company's cost structure needs to be addressed...."
Amylin, in addition to the two announcements this week, has been making its case to shareholders.
The AMLN shareholder meeting is May 27th. Looks like it could be a barnburner.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
